# Thymulin Lung Research: Asthma, Airway Remodeling, and Pulmonary Hypertension > Thymulin lung research, decoded: a single inhaled gene-therapy dose reversed established asthma pathology in mice, DNA-nanoparticle delivery prevented airway remodeling, and thymulin attenuated pulmonary hypertension in rats. All cited. One inhaled dose reversed established asthma pathology in mice at 20 days. Here is that result — and the rest of the lung record — read straight from the studies. ## In plain English This is the headline page. Thymulin lung research is the most striking part of the whole record, and the standout is a 2020 mouse study: scientists packed the thymulin gene into tiny mucus-penetrating particles, gave a single dose straight into the airway after asthma was already fully established, and 20 days later the key lung problems had normalized [7]. Other studies stopped airway scarring before it formed [10] and calmed a kind of high lung blood pressure in rats [8]. Important: these are animal models. None of this is an asthma or lung treatment for people. ## The comeback: a single inhaled dose reversed established asthma pathology This is the result that put thymulin on the lung-research map. In mice with experimental allergic asthma that was already fully and stably established, a single intratracheal dose of thymulin-expressing plasmids — delivered in mucus-penetrating nanoparticles — normalized all key lung pathologies at 20 days: chronic inflammation, pulmonary fibrosis, and mechanical dysregulation, via anti-inflammatory and antifibrotic effects [7]. The word established matters. The treatment was given after disease, not before, so this reads as therapeutic reversal rather than prevention [7]. One dose. Twenty days. A near-complete normalization of established asthma pathology in the model. That is the comeback-from-the-brink beat — and it is a mouse gene-therapy finding, reported exactly as the study reported it [7]. ## Stopping the remodel before it starts Asthma does not just inflame airways — over time it remodels them, thickening and scarring the walls. A separate study attacked that structural change directly: DNA nanoparticle-mediated thymulin gene therapy prevented airway remodeling in experimental allergic asthma in mice [10]. Together, the two airway studies bracket the disease. One prevents the structural remodeling [10]; the other reverses established inflammatory, fibrotic, and mechanical pathology [7]. Both are gene-therapy approaches — the thymulin payload is delivered as a plasmid, not injected as a peptide — and both are mouse-model results, not human protocols. ## Pulmonary hypertension: calming the pressure in rats Thymulin's lung story extends to the pulmonary blood vessels. In adult rats, thymulin inhibited monocrotaline-induced pulmonary hypertension — a standard model of high blood pressure in the lung's arteries — by modulating interleukin-6 expression and suppressing the p38 MAPK pathway, at roughly 100 ng/kg/day subcutaneous [8]. The mechanism rhymes with the rest of the record: an inflammatory mediator (IL-6) turned down, a stress-signaling pathway (p38) suppressed [8]. It is the same anti-inflammatory logic that shows up in the NF-kB work [6], pointed at the lung vasculature. A rat-model finding, framed as such. ## Why the lung keeps showing up A 2010 review pulled the lung work together, summarizing thymulin's immunomodulatory role across multiple experimental lung-disease models and reporting consistent beneficial effects [9]. The throughline is mechanistic coherence: thymulin's anti-inflammatory and immunomodulatory action — NF-kB suppression [6], cytokine modulation [8], antifibrotic effects [7] — keeps landing in lung tissue across asthma, airway remodeling, and pulmonary hypertension models [9]. That coherence is genuinely promising and genuinely preclinical. The lung findings are some of the strongest in the thymulin literature, and they are animal and gene-therapy results. There are no large human efficacy trials of native thymulin for any lung condition. Read the [thymulin research findings](/research) for the mechanism behind these effects, and the [frequently asked questions about thymulin](/faq) for the short answers. ## Has thymulin been studied for asthma? Yes — in mice. A single intratracheal dose of thymulin-expressing plasmids in mucus-penetrating nanoparticles, given after experimental allergic asthma was fully established, normalized key lung pathologies (chronic inflammation, fibrosis, mechanical dysregulation) at 20 days [7]. A separate DNA-nanoparticle approach prevented airway remodeling [10]. These are animal-model findings only — not an asthma treatment for people. --- A high-energy reading of the thymulin record drawn panel by panel — the zinc power-up that switches the nonapeptide on, the T-cell and lung findings, and the missing human trials all inked from the published studies; no clinic behind the page and nothing here dosed, dispensed, or sold.